Amarin Corporation

Please note: The information displayed on this page might be outdated.
Amarin Corporation: Their lead commercial product, VASCEPA® (icosapent ethyl), is the only pure EPA omega-3 fatty acid approved for prophylactic cardiovascular health. . Efficacy and safety profile of VASCEPA, demonstrated in the REDUCE-IT® cardiovascular outcomes study, seen as largest breakthrough in preventative cardiovascular care in 30 years. Q1 net product revenue was 140.2 million dollars. Received EU marketing authorization Q1 2021.
Based in...
US - Middle Atlantic
Clinical Stage
Disease Space
Biotechnology, Pharmaceuticals
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Small Molecule
1430 Route 206
Suite 200
Bedminster, NJ 07921
United States

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

  • Karim Mikhail, CEO

Top 10 Holders of Amarin Corporation Plc Sponsored ADR

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Sarissa Capital Management LP 6.05 24,000,000 34.08 13F 3/31/22
Baker Bros. Advisors LP 5.34 21,169,805 30.06 13F 3/31/22
Eversept Partners LP 2.26 8,980,145 12.75 13F 3/31/22
SCP Investment LP 1.70 6,750,000 9.59 13F 3/31/22
Avoro Capital Advisor LLC 1.51 6,000,000 8.52 13F 3/31/22
Stonepine Capital Management LLC 1.24 4,912,714 6.98 13F 3/31/22
Millennium Management LLC 1.23 4,885,384 6.94 13F 3/31/22
ClearBridge Investments LLC 1.21 4,789,575 6.80 13F 3/31/22
Rock Springs Capital Management LP 1.11 4,419,700 6.28 13F 3/31/22
DG Capital Management LLC 1.10 4,344,485 6.17 13F 3/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.